AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14564602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7% sevoflurane
Number of subjects: 12
Study 8941005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) treatment at doses of 600, 800 or 1200 mg/day
Number of subjects: 21
Study 8941005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) treatment
Number of subjects: 21
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (controlled release)
Number of subjects: 1627
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1627
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 1627
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride (diuretic)
Number of subjects: 1627
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary treatment (beta-blocker to diuretic, or vice versa)
Number of subjects: 1627
Study 1338084 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment regimens
Number of subjects: 1627
Study 6372360 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg PGE2 pessary
Number of subjects: 180
Study 6372360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 pessary
Number of subjects: 180
Study 6372360 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg PGE2 pessary
Number of subjects: 180
Study 31044234 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended pregnancy
Number of subjects: 400
Study 30356308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (2% bodyweight deficit) during high heat stress (HYPER)
Number of subjects: 139
Study 30356308 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration during high heat stress (HYPER)
Number of subjects: 139
Study 30356308 — intervention group
Group type: COMPARATOR
Intervention: Moderate heat stress (MOD)
Number of subjects: 139
Study 30356308 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (full fluid replacement)
Number of subjects: 139
Study 28211106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) intervention
Number of subjects: 30
Study 28211106 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 30
Study 25786769 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 11
Study 25786769 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg q.d.
Number of subjects: 11
Study 25786769 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 10 mg q.d.
Number of subjects: 11
Study 23174486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy defibrillator (CRT-D)
Number of subjects: 1209
Study 23174486 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1209
Study 23174486 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in LBBB patients
Number of subjects: 1209
Study 23174486 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in non-LBBB patients
Number of subjects: 1209
Study 21999631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily
Number of subjects: 152
Study 21999631 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) 300/100 mg once daily
Number of subjects: 152
Study 18456465 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin extended release (AZ‐ER) 2g single dose
Number of subjects: 9
Study 18456465 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin immediate release (AZ‐IR) 500mg daily for 3 days
Number of subjects: 9
Study 16801649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in DLB patients
Number of subjects: 89
Study 16801649 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed H/M ratio in DLB patients
Number of subjects: 89
Study 16801649 — intervention group
Group type: COMPARATOR
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in AD patients
Number of subjects: 89
Study 16801649 — intervention group
Group type: COMPARATOR
Intervention: Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy in DLB/P+ and DLB/P- patients
Number of subjects: 89
Study 14528776 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric Acid (PA) etching with Prime & Bond NT (PBNT) on permanent dentin (Group I)
Number of subjects: 40
Study 14528776 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric Acid (PA) etching with Prime & Bond NT (PBNT) on primary dentin (Group II)
Number of subjects: 40
Study 14528776 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (NRC) with Prime & Bond NT (PBNT) on permanent dentin (Group III)
Number of subjects: 40
Study 14528776 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (NRC) with Prime & Bond NT (PBNT) on primary dentin (Group IV)
Number of subjects: 40
Study 11205362 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study 11205362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of viral infection episodes
Number of subjects: 0
Study 11205362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 0
Study 9488243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (n = 11)
Number of subjects: 25
Study 9488243 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (n = 13)
Number of subjects: 25
Study 9488243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study 9488243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 25
Study 9488243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and Lisinopril
Number of subjects: 25
Study 8453797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroids
Number of subjects: 25
Study 8453797 — intervention group
Group type: COMPARATOR
Intervention: Bed rest only
Number of subjects: 25
Study 2426829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 51
Study 2426829 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion
Number of subjects: 51
Study 30272096 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP Group (physical training using the HBP)
Number of subjects: 20
Study 30272096 — intervention group
Group type: COMPARATOR
Intervention: Exercise Group (training without the use of the orthosis)
Number of subjects: 20
Study 26321012 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-Plus intervention (coach-directed dietary advice, assistance with online ordering and purchasing of high-potassium foods, $30/week)
Number of subjects: 123
Study 26321012 — intervention group
Group type: COMPARATOR
Intervention: Control group (printed DASH diet brochure, debit account of equivalent value)
Number of subjects: 123
Study 23742737 — intervention group
Group type: EXPERIMENTAL
Intervention: nabiximols (oral mucosal spray containing cannabinoids)
Number of subjects: 16
Study 23742737 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 23538392 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention with diaries and therapist feedback
Number of subjects: 140
Study 23538392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone intervention)
Number of subjects: 140
Study 20723437 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial perfusion of batroxobin combined with TACE
Number of subjects: 40
Study 20723437 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 40
Study 18466670 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 289
Study 18466670 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 289
Study 16636857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual androstenediol (SL-DIOL) with exercise (EX)
Number of subjects: 6
Study 16636857 — intervention group
Group type: COMPARATOR
Intervention: Sublingual androstenediol (SL-DIOL) without exercise (Rest)
Number of subjects: 6
Study 16636857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual androstenediol (SL-DIOL)
Number of subjects: 6
Study 12897317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention (6 to 11 sessions, including separate meetings with parents and children)
Number of subjects: 121
Study 12897317 — intervention group
Group type: COMPARATOR
Intervention: Lecture intervention (2 separate meetings in a group format without children present)
Number of subjects: 121
Study 12897317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Clinician-facilitated and Lecture)
Number of subjects: 121
Study 10711585 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 1192
Study 10711585 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 1192
Study 10711585 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1192
Study 10711585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1192
Study 9005501 — intervention group
Group type: EXPERIMENTAL
Intervention: IHB before incision using 0.25 ml/kg bupivacaine 0.5%
Number of subjects: 68
Study 9005501 — intervention group
Group type: EXPERIMENTAL
Intervention: IHB after incision using 0.25 ml/kg bupivacaine 0.5%
Number of subjects: 68
Study 9005501 — intervention group
Group type: COMPARATOR
Intervention: IHB before incision with 0.25 ml/kg of serum
Number of subjects: 68
Study 9005501 — intervention group
Group type: COMPARATOR
Intervention: IHB after incision with 0.25 ml/kg of serum
Number of subjects: 68
Study 8151594 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms oral dose)
Number of subjects: 8
Study 8151594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3167937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (high nicotine content)
Number of subjects: 6
Study 3167937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (low nicotine content)
Number of subjects: 6
Study 3167937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum chewing
Number of subjects: 6
Study 3167937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study 29480182 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous memory training and aerobic exercise (SIM)
Number of subjects: 55
Study 29480182 — intervention group
Group type: COMPARATOR
Intervention: Sequential memory training after stationary cycling (SEQ)
Number of subjects: 55
Study 28199799 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g protein hydrolysate
Number of subjects: 24
Study 28199799 — intervention group
Group type: COMPARATOR
Intervention: iso-caloric carbohydrate
Number of subjects: 24
Study 28199799 — intervention group
Group type: COMPARATOR
Intervention: low-calorific placebo
Number of subjects: 24
Study 25785646 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Directed Interaction Training (CDIT)
Number of subjects: 30
Study 23930444 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support group
Number of subjects: 40
Study 23930444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21381272 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options
Number of subjects: 0
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomograms (OCT) with erroneous centerpoint thickness needing manual remeasurement (MR)
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related macular degeneration (AMD)
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vein occlusion
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic macular edema
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Boundary line errors
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentration artifact
Number of subjects: 6741
Study 19373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Median absolute difference between machine and manually measured centerpoint thickness
Number of subjects: 6741
Study 17545057 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable lingual arch plus auxiliary spring
Number of subjects: 17
Study 17545057 — intervention group
Group type: COMPARATOR
Intervention: Quad-helix
Number of subjects: 17
Study 15065730 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 1061
Study 15065730 — intervention group
Group type: COMPARATOR
Intervention: Routine mailing only
Number of subjects: 1061
Study 11488742 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mercurochrome applied for 48 hours before surgery
Number of subjects: 44
Study 11488742 — intervention group
Group type: COMPARATOR
Intervention: Conventional local scrub with soap/water
Number of subjects: 44
Study 9503217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg)
Number of subjects: 25
Study 9503217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7567201 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct extubation from IMV (D.EXT)
Number of subjects: 87
Study 7567201 — intervention group
Group type: EXPERIMENTAL
Intervention: Preextubation endotracheal CPAP (ET‐CPAP) for 12‐24 hr
Number of subjects: 87
Study 7567201 — intervention group
Group type: EXPERIMENTAL
Intervention: Postextubation nasopharyngeal CPAP (NP‐CPAP) for 12‐24 hr
Number of subjects: 87
Study 7567201 — intervention group
Group type: COMPARATOR
Intervention: Preextubation endotracheal CPAP (ET‐CPAP)
Number of subjects: 87
Study 7567201 — intervention group
Group type: COMPARATOR
Intervention: Postextubation nasopharyngeal CPAP (NP‐CPAP)
Number of subjects: 87
Study 2356812 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (5 cups per day for 6 weeks)
Number of subjects: 45
Study 2356812 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (5 cups per day for 6 weeks)
Number of subjects: 45
Study 391625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg given once daily
Number of subjects: 40
Study 391625 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg given b.i.d.
Number of subjects: 40
Study 31610616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg oral, 1 hour preprocedure
Number of subjects: 26
Study 30298469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC) as first-line chemotherapy
Number of subjects: 307
Study 30298469 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset of patients receiving GC therapy
Number of subjects: 307
Study 28715589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 44 μg
Number of subjects: 347
Study 28715589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 440 μg
Number of subjects: 347
Study 28715589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 880 μg
Number of subjects: 347
Study 28715589 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VFR
Number of subjects: 347
Study 25762863 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus diet (RT + diet)
Number of subjects: 7
Study 25762863 — intervention group
Group type: COMPARATOR
Intervention: Diet control group
Number of subjects: 7
Study 23201174 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline 2mg
Number of subjects: 38
Study 23201174 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 21508083 — intervention group
Group type: COMPARATOR
Intervention: Neutral position technique (group A, n=17)
Number of subjects: 35
Study 21508083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextended internal rotation technique (group B, n=18)
Number of subjects: 35
Study 18431091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 3 months
Number of subjects: 184
Study 18431091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 16567343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (PR)
Number of subjects: 60
Study 16567343 — intervention group
Group type: COMPARATOR
Intervention: Propofol-alfentanil (PA)
Number of subjects: 60
Study 16567343 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of wake-up test
Number of subjects: 60
Study 14681961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronoran (piribedil) combined with levodopa, dosage 50-150 mg daily for 6 months
Number of subjects: 99
Study 14681961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 11065032 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthing centre care
Number of subjects: 201
Study 11065032 — intervention group
Group type: COMPARATOR
Intervention: Delivery suite care
Number of subjects: 201
Study 1942321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to increase hydration (group 1, 57 patients)
Number of subjects: 140
Study 1942321 — intervention group
Group type: COMPARATOR
Intervention: No dietary advice (group 2, 83 patients)
Number of subjects: 140
Study 1942321 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of urine specific gravity dipsticks (24 patients)
Number of subjects: 140
Study 7029740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol tartrate 100 mg and chlorthalidone 25 mg
Number of subjects: 71
Study 31993665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight sleep deprivation (complete nighttime wakefulness)
Number of subjects: 35
Study 31993665 — intervention group
Group type: COMPARATOR
Intervention: Nighttime sleep (10 pm to 6 am)
Number of subjects: 35
Study 31993665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight sleep deprivation
Number of subjects: 35
Study 30937656 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane plus anthracycline (TA)
Number of subjects: 640
Study 30937656 — intervention group
Group type: COMPARATOR
Intervention: Taxane plus anthracycline plus cyclophosphamide (TAC)
Number of subjects: 640
Study 30030413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lente insulin
Number of subjects: 30
Study 30030413 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 30
Study 26999053 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1287
Study 26999053 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1287
Study 26999053 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and Women
Number of subjects: 1287
Study 24942594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% E6005 ointment
Number of subjects: 78
Study 24942594 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 78
Study 22201654 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching
Number of subjects: 318
Study 22201654 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized education
Number of subjects: 318
Study 22201654 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 318
Study 20107767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic organ prolapse quantification (POP-Q) assessment by physiotherapists
Number of subjects: 45
Study 20107767 — intervention group
Group type: COMPARATOR
Intervention: Examination by gynaecologists
Number of subjects: 45
Study 18083473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous (IV) 50 mg flurbiprofen (group F)
Number of subjects: 25
Study 18083473 — intervention group
Group type: COMPARATOR
Intervention: Not receiving flurbiprofen (group C)
Number of subjects: 25
Study 16216607 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) at 40 Hz
Number of subjects: 19
Study 16216607 — intervention group
Group type: COMPARATOR
Intervention: Signal-averaged ECG (SAECG)
Number of subjects: 19
Study 16216607 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) for root mean square of the last 40 milliseconds of atrial signal
Number of subjects: 19
Study 16216607 — intervention group
Group type: COMPARATOR
Intervention: Signal-averaged ECG (SAECG) for root mean square of the last 40 milliseconds of atrial signal
Number of subjects: 19
Study 12374716 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal (LMA‐PS)
Number of subjects: 109
Study 12374716 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 109
Study 9926950 — intervention group
Group type: EXPERIMENTAL
Intervention: midvastus approach
Number of subjects: 24
Study 9926950 — intervention group
Group type: COMPARATOR
Intervention: standard parapatellar approach
Number of subjects: 24
Study 7755058 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical arteries of babies born to smoking mothers
Number of subjects: 27
Study 7755058 — intervention group
Group type: COMPARATOR
Intervention: Umbilical arteries of babies born to nonsmoking mothers
Number of subjects: 27
Study 2087438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (0.5 nmol)
Number of subjects: 19
Study 2087438 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine (0.5 nmol)
Number of subjects: 19
Study 2087438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of bradykinin and 5-hydroxytryptamine (0.25 nmol + 0.25 nmol)
Number of subjects: 19
Study 2087438 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 19
Study 7124315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin
Number of subjects: 30
Study 7124315 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 30
Study 31720788 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation by pulmonary vein isolation (PVI)
Number of subjects: 0
Study 31720788 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 0
Study 31720788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power short-duration ablation (HPSD)
Number of subjects: 0